| ²é¿´: 328 | »Ø¸´: 3 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
zqxia2009Ìú¸Ëľ³æ (ÕýʽдÊÖ)
|
[½»Á÷]
ÓÐЩµØ·½·Òë²»ºÃ£¬ÇëÇó°ïÖú
|
||
| Figure 6 shows the cumulative percentages of patients from each of the treatment groups who had attained at least the measure of improvement in the ADCS-ADL shown on the X axis.The curves show that both patients assigned to NAMENDA/donepezil and placebo/donepezil have a wide range of responses and generally show deterioration, but that the NAMENDA/donepezil group is more likely to show a smaller decline or an improvement¡£ |
» ²ÂÄãϲ»¶
ÉúÎïѧ303Çóµ÷¼Á£¬Ò»Ö¾Ô¸»ªÖÐũ΢ÉúÎÁù¼¶Òѹý£¬ÓпÆÑÐÓÐÎÄÕ£¬µ³Ô±
ÒѾÓÐ4È˻ظ´
318Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
0703µ÷¼Á
ÒѾÓÐ11È˻ظ´
»¯Ñ§357·Ö£¬¿¼Ñе÷¼Á
ÒѾÓÐ10È˻ظ´
0854Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
272Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
µ÷¼ÁÇóÖú
ÒѾÓÐ13È˻ظ´
332Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
341Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Ò»Ö¾Ô¸µç×ӿƼ¼´óѧ085600²ÄÁÏÓ뻯¹¤ 329·ÖÇóµ÷¼Á
ÒѾÓÐ10È˻ظ´
benmao_mogu
ľ³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 51
- Ó¦Öú: 16 (СѧÉú)
- ½ð±Ò: 4930.7
- É¢½ð: 2657
- ºì»¨: 24
- Ìû×Ó: 1540
- ÔÚÏß: 198.4Сʱ
- ³æºÅ: 992763
- ×¢²á: 2010-04-09
- ÐÔ±ð: GG
- רҵ: »¯Ñ§·´Ó¦¹¤³Ì
¡ï
zqxia2009(½ð±Ò+1, ·ÒëEPI+1): 2010-04-19 13:37
sirljz(½ð±Ò+1):лл½»Á÷£¬ºÜ»ý¼«£¬»¶Ó³£À´ 2010-04-19 15:50
zqxia2009(½ð±Ò+1, ·ÒëEPI+1): 2010-04-19 13:37
sirljz(½ð±Ò+1):лл½»Á÷£¬ºÜ»ý¼«£¬»¶Ó³£À´ 2010-04-19 15:50
| ͼ6ÏÔʾÁËÿһ×鲡ÈËÖÎÁƵÄÀÛ»ýÒÑ´ïµ½µÄ°Ù·Ö±È±íÃ÷ÖÁÉÙÔÚADCµÄ- ADLµÄ¸ÄÉÆ¶ÔX axis.ÇúÏß±íÃ÷·ÖÅ䏸NAMENDA /¶àÄÎß߯ë×éºÍ°²Î¿¼Á/¶àÄÎß߯ëÁ½Ãû»¼ÕßÓÐ׏㷺µÄ·´Ó¦²¢ÆÕ±é±íÏÖ³ö¶ñ»¯£¬µ«¸ÃNAMENDA /¶àÄÎß߯ë×é¸ü¿ÉÄÜÕ¹ÏÖ³öÉÔ΢µÄϽµ»ò¸ÄÉÆ¡£ |

3Â¥2010-04-19 11:12:09
2Â¥2010-04-19 08:55:07
zqxia2009
Ìú¸Ëľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 6096.7
- ºì»¨: 1
- Ìû×Ó: 637
- ÔÚÏß: 106.2Сʱ
- ³æºÅ: 890958
- ×¢²á: 2009-11-02
- ÐÔ±ð: MM
- רҵ: Ò©Îï·ÖÎö
4Â¥2010-04-19 13:45:11














»Ø¸´´ËÂ¥